Sanofi (SNY)
(Delayed Data from NSDQ)
$51.32 USD
-0.41 (-0.79%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $51.31 -0.01 (-0.02%) 7:04 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.32 USD
-0.41 (-0.79%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $51.31 -0.01 (-0.02%) 7:04 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Top Analyst Reports for Novo Nordisk, NextEra & 3M Company
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), NextEra Energy (NEE), and 3M Company (MMM).
Translate (TBIO) Down on Unsatisfactory CF Drug Study Results
by Zacks Equity Research
Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.
Pharma Stock Roundup: J&J, AZN COVID-19 Update, FDA Delays Decision on ABBV's sNDA
by Kinjel Shah
WHO gives EUL to J&J's (JNJ) COVID-19 vaccine. FDA pushes back review on AbbVie's (ABBV) sNDA
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.
Regeneron (REGN), Sanofi's Libtayo Positive for Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi announce favorable data on their oncology drug Libtayo from a phase III study on cervical cancer.
Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage
by Zacks Equity Research
The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.
Sanofi's (SNY) Dupixent sBLA for Asthma Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Sanofi's (SNY) sBLA for review of Dupixent for treating moderate-to-severe asthma in children aged six-11 years. A verdict from the FDA is expected on Oct 21, 2021.
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold
by Zacks Equity Research
Amicus (FOLD) reports a wider-than-expected Q4 loss but sales beat estimates.
Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.
Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal
by Zacks Equity Research
Denali (DNLI) posts earnings in the fourth quarter of 2020 due to collaboration revenues from Biogen.
Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout
by Kinjel Shah
Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion
BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Incyte (INCY) and Nektar (NKTR).
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Emergent (EBS) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
Emergent's (EBS) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Sales of contract development and manufacturing services rise.
Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ
by Kinjel Shah
WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.
Glaxo (GSK)/Vir Biotech to Develop Antibodies for Influenza
by Zacks Equity Research
Glaxo (GSK)/Vir Biotech expands their existing coronavirus collaboration for developing new monoclonal antibody candidates for influenza and other respiratory viruses.
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
Alnylam's (ALNY) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Alnylam (ALNY) reported a wider-than-expected loss but revenues beat estimates in the fourth quarter of 2020.
Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs
by Kinjel Shah
AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.
Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates
by Zacks Equity Research
Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.
Sanofi (SNY)/Regeneron's Libtayo Gets FDA Nod for 2nd Indication
by Zacks Equity Research
The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.
Regeneron (REGN) Q4 Earnings, Sales Beat on Solid Dupixent Show
by Zacks Equity Research
Regeneron (REGN) beats on Q4 earnings and sales on solid performance of Dupixent, Eylea and incremental contribution from oncology drug, Libtayo.